CellRight Technologies, a Tissue Regenix Group company, processes, stores, and distributes Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) to hospitals, medical professionals, and approved distribution partners in compliance with the requirements of the FDA and state regulations, AATB Standards, and other foreign requirements. We are AATB accredited and registered with the FDA.
CellRight Technologies, a leading manufacturer of lot verified osteoinductive allografts, provides innovative matrices with superior handling crucial to clinical practice. All allograft products are processed using our proprietary BioRinse® sterilization technology, designed to preserve native BMP's.
Exceptional care and quality, coupled with scientific knowledge, provide the foundation for the development of extraordinary allograft products that impact patient healing.
From its inception, CellRight Technologies has the challenging patient in mind when developing its technology and verified osteoinductive allografts. We are very conscious of the current and future state of healthcare; our products are designed to contribute to “Triple Aim.” We have created and will continue to create innovative allografts that address the following: INFECTION CONTROL - Can be an alternative to an autograft surgical procedure, which eliminates the possibility of infection at the second surgery site CLINICAL VALUE - Verification for osteoinductivity; every lot, post-sterilization via in-vivo test - Help influence better fusion rates - Great wicking capacity for autologous blood - Grafts reconstitute within minutes - Graft containment within the defect ECONOMIC VALUE - Cost effective versus alternatives - Reduce hospital stay of patients (e.g. autograft procedures) - Help influence better patient outcomes - Eliminate waste of expensive cellular therapies (e.g. BMA) UNMET NEED - 100% human derived allograft with great handling properties - High resorption rate of DBM sponge-like products - Deployment of DBM putty through smaller cannulas - Deployment of DBM cortical fibers through cannulas INNOVATION - Founder is co-inventor of the “cancellous sponge” - BioRinse™ is next generation processing technology
